Drug intelligence / Profile preview

dezapelisib

Development stage: Phase 1
Lead developer: Incyte
Modality: Small Molecules
Administration: Oral

Overview

Dezapelisib is an investigational small molecule inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ). It is designed to selectively inhibit the PI3Kδ isoform, a key signaling protein involved in the proliferation and survival of B cells. By blocking this pathway, dezapelisib aims to reduce abnormal cell growth and survival in certain hematologic malignancies such as lymphomas and leukemias. The drug was developed by Incyte for use primarily in B-cell malignancies.

Other names: INCB050465INCB-050465INCB 050465

Targets

PIK3CD (Phosphatidylinositol 3-kinase delta)

Beyond the preview

Go deeper on dezapelisib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dezapelisib.

Explore the full profile